Novel targets that affect high-density lipoprotein metabolism: the next frontier.
As the significance of treating coronary artery disease (CAD) remains a high priority in reducing morbidity and mortality worldwide, newer treatment strategies continue to evolve. The efficacy of statin therapy in reducing low-density lipoprotein cholesterol and reducing cardiovascular events is well established. Yet, addressing residual macrovascular risk becomes a compelling rationale for proposing that pharmacologic therapy targeted at low concentrations of high-density lipoprotein (HDL) cholesterol is a rationale target for enhanced management of CAD. This article reviews current options for the therapeutic management of HDL cholesterol, including discussion of novel agents aimed at reducing cardiovascular disease risk in patients with low levels of HDL cholesterol.
Davidson
Michael H
MH
University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA. Michaeldavidson@radiantresearch.com
Rosenson
Robert S
RS
D016632:Apolipoprotein A-I / Q000627:therapeutic use; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors; D008076:Cholesterol, HDL / Q000378:metabolism*; D002986:Clinical Trials as Topic; D002995:Clofibric Acid / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D009525:Niacin / Q000627:therapeutic use
D016632:Apolipoprotein A-I; C506642:CETP protein, human; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D009525:Niacin; D002995:Clofibric Acid